Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netopitampalonosetron vs ondansetron for prevention of radiotherapy-induced nausea and vomiting in lower esophageal malignancies
ChiCTR2400088072Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of netupitant + palonosetron in esophageal cancer (2 arms), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Complete response during radiotherapy. Started Aug 2024; status: recruiting.
02
Drugs
netupitant + palonosetron
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2400088072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088072.